Announcements
Projects
Orgs
Project
Articles 6
Votes 0
Lilly.com

Authors 3

Investors
Eli Lilly
Company
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight - Eli Lilly
27d
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - Eli Lilly
28d
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly
~2mo
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis | Eli Lilly and Company - Investors | Eli Lilly and Company
>2y
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology | Eli Lilly and Company - Investors | Eli Lilly and Company
>2y
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease | Eli Lilly and Company - Investors | Eli Lilly and Company
almost3y